Core Viewpoint - The company has adjusted the total amount of funds to be raised through the issuance of convertible bonds from RMB 1,801.34 million to RMB 1,292.39 million, reflecting a strategic response to current market conditions and project implementation arrangements [2][3]. Fundraising Adjustment - The total amount of funds to be raised through the issuance of convertible bonds has been reduced from RMB 1,801.34 million to RMB 1,292.39 million [2][3]. - The planned investment for the project of producing 30,000 tons of allulose and 5,000 tons of inositol has been adjusted accordingly, with the total planned investment amount now being RMB 1,396.56 million [3]. Project Funding Strategy - Before the funds are in place, the company can use self-raised funds for initial investments based on actual project conditions, which will be replaced by the raised funds once available [2][3]. - Any portion of the total investment amount exceeding the raised funds will be financed by the company through self-raised funds [2][3]. - The board of directors or authorized personnel may adjust the order and amount of fund allocation for the projects based on urgency, without changing the intended investment projects [2][3].

（文章来源：证券日报） 证券日报网讯 8月5日晚间，金达威发布公告称，公司第九届董事会第三次会议审议通过了《关于调整 公司向不特定对象发行可转换公司债券募集资金规模的议案》。 ...

（文章来源：每日经济新闻） 2024年1至12月份，金达威的营业收入构成为：工业占比97.88%，医药原料占比1.94%，其他业务占比 0.18%。 金达威（SZ 002626，收盘价：20.31元）8月5日晚间发布公告称，公司第九届第三次董事会会议于2025 年8月5日在厦门市海沧区公司五层会议室以现场结合通讯表决的方式召开。会议审议了《关于调整公司 向不特定对象发行可转换公司债券募集资金规模的议案》等文件。 ...

募集资金规模的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开 第九届董事会第三次会议审议通过了《关于调整公司向不特定对象发行可转换公 司债券募集资金规模的议案》。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券发 行注册管理办法》等法律、法规和规范性文件的相关规定，公司董事会结合公司 实际情况、项目实施安排及当前市场状况等因素，现将本次向不特定对象发行可 转换公司债券的募集资金总额由不超过人民币 180,134.38 万元（含本数）调整为 不超过人民币 129,239.48 万元（含本数），本次募集资金投资项目对应拟投入募 集资金金额亦作相应调整，具体如下： 调整前： 公司本次向不特定对象发行可转换公司债券募集资金总额不超过 180,134.38 万元（含本数），扣除发行费用后的募集资金净额拟投资于以下项目： 证券代码：002626 证券简称：金达威 公告编号：2025-062 厦门金达威集团股份有限公司 关于调整公司向不特定对象发行可转换公司债券 在 ...

一、 会议以 9 票同意、0 票反对、0 票弃权的表决结果审议通过《关于调 整公司向不特定对象发行可转换公司债券募集资金规模的议案》 证券代码：002626 证券简称：金达威 公告编号：2025-061 厦门金达威集团股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）第九届董事会第三次会 议于 2025 年 8 月 5 日在厦门市海沧区公司五层会议室以现场结合通讯表决的方 式召开。本次会议通知已于 2025 年 8 月 1 日以通讯方式发出，并获全体董事确 认。本次会议由董事长江斌先生主持，公司董事会成员应到九人，实际参加表决 人数九人。公司副总经理、财务总监、董事会秘书等高级管理人员亦列席了本次 会议。本次会议的召集、召开符合《中华人民共和国公司法》和公司章程的有关 规定。 经与会董事认真审议，本次会议以现场结合通讯表决的方式审议通过了以下 议案： 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券发 行注册管理办法》等法律、法规和规范性文件的相关规定， ...

Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

Core Viewpoint - The establishment of a joint venture, Jindawei (Inner Mongolia) Nutritional Food Co., Ltd., between Jindawei Pharmaceutical and Aibede Life Science Research Institute aims to enhance product absorption efficiency and competitiveness in the global market [1] Group 1 - The joint venture is located in the industrial park of Tokto County, Hohhot City, Inner Mongolia [1] - The collaboration will leverage nanocrystal production technology for products such as Coenzyme Q10, Astaxanthin, Curcumin, and Quercetin [1] - The application of this technology is expected to significantly improve the absorption speed and efficiency of the company's related products [1]

Core Viewpoint - The establishment of a joint venture, Jindawei (Inner Mongolia) Nutritional Food Co., Ltd., between Jindawei Pharmaceutical and Aibede Life Science Research Institute aims to enhance product absorption efficiency and competitiveness in the global market [1] Group 1 - Jindawei Pharmaceutical has received notification regarding the establishment of a joint venture in Hohhot, Inner Mongolia [1] - The joint venture will utilize nanocrystal production technology for products such as coenzyme Q10, astaxanthin, curcumin, and quercetin [1] - The application of this technology is expected to significantly improve the absorption speed and efficiency of the company's related products [1] Group 2 - The collaboration is intended to deepen cooperation between Jindawei and Aibede, benefiting both companies in the nutritional health sector for humans and pets [1] - The technology's implementation is anticipated to enhance the company's product competitiveness [1] - This initiative is aligned with the company's strategy to expand its business in the global market [1]

Core Viewpoint - The establishment of a joint venture between Jindawei Pharmaceutical and Aibede Life Science Research Institute aims to enhance the absorption efficiency of various health products through advanced nanocrystal production technology [1] Group 1: Joint Venture Details - Jindawei Pharmaceutical has received notification regarding the establishment of a joint venture with Aibede in Hohhot, Inner Mongolia [1] - The joint venture will focus on applying nanocrystal production technology to products such as Coenzyme Q10, Astaxanthin, Curcumin, and Quercetin [1] Group 2: Strategic Implications - The collaboration is expected to significantly improve the absorption speed and efficiency of the related products [1] - The applications of these enhanced products will extend to both human and pet nutritional health [1]

Core Viewpoint - The establishment of a joint venture by Kingdawei and Aibede in Inner Mongolia focuses on the nutrition food sector, leveraging nanocrystal technology to enhance the bioavailability of fat-soluble nutrients, aligning with the company's long-term development strategy [1] Group 1 - Kingdawei's wholly-owned subsidiary, Kingdawei Pharmaceutical, has partnered with Aibede to create a joint venture named Kingdawei (Inner Mongolia) Nutrition Food Co., Ltd [1] - The registered capital of the joint venture is 5 million yuan, with Kingdawei Pharmaceutical investing 3 million yuan for a 60% stake, while Aibede invests 2 million yuan for a 40% stake [1] - The joint venture aims to improve product competitiveness in the nutrition food industry through advanced technology [1]